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Abstract
Mitochondrial complex I, the primary entry point for electrons into the mitochondrial respiratory chain, is both critical for
aerobic respiration and a major source of reactive oxygen species. In the heart, chronic dysfunction driving cardiomyopathy
is frequently associated with decreased complex I activity, from both genetic and environmental causes. To examine the
functional relationship between complex I disruption and cardiac dysfunction we used an established mouse model of mild
and chronic complex I inhibition through heart-specific Ndufs4 gene ablation. Heart-specific Ndufs4-null mice had a
decrease of ,50% in complex I activity within the heart, and developed severe hypertrophic cardiomyopathy as assessed by
magnetic resonance imaging. The decrease in complex I activity, and associated cardiac dysfunction, occurred absent an
increase in mitochondrial hydrogen peroxide levels in vivo, accumulation of markers of oxidative damage, induction of
apoptosis, or tissue fibrosis. Taken together, these results indicate that diminished complex I activity in the heart alone is
sufficient to drive hypertrophic cardiomyopathy independently of alterations in levels of mitochondrial hydrogen peroxide
or oxidative damage.
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Introduction
The heart is particularly susceptible to mitochondrial dysfunc-
tion due to its strict dependence on aerobic metabolism [1,2].
Indeed, disruptions in mitochondrial bioenergetics are thought to
underlie a variety of chronic myocardial pathologies [3,4].
However, there are a variety of mechanisms by which mitochon-
drial dysfunction can drive chronic myocardial pathology. A
common feature of mitochondrial dysfunction in the heart is
disruption to mitochondrial complex I, caused either by mutation
in the genes required to generate a fully functional complex or
cumulative damage to the complex itself [5–9]. Mitochondrial
complex I is the primary entry point for electrons into the
mitochondrial respiratory chain and thereby plays an essential role
in generating the mitochondrial membrane potential [10],
determining the NADH/NAD+ ratio [11], and is also a major
source of the reactive oxygen species (ROS) superoxide [12].
Importantly, disruption to all or any of these processes contributes
to downstream activation of apoptotic and necrotic cell death
pathways [13].
As persistent disruption of complex I activity from a range of
causes is frequently observed in cardiomyopathies [5,8,9,14–16],
we sought to assess directly the consequence of persistent
functional disruption of mitochondrial complex I in the heart
alone. Disruption to complex I activity could contribute to cell
dysfunction through a variety of mechanisms. Dysfunction could
be driven by decreasing the mitochondrial membrane potential
that would in turn lead to defective ATP synthesis and/or calcium
homeostasis [13]. Alternatively, complex I disruption could drive
pathology through a buildup of mitochondrial NADH that in turn
can drive increased superoxide formation from the flavin site of
complex I, or from other sources [12,17,18].
To assess the potential primary role of complex I disruption in
driving cardiomyopathy through these processes, we chose to
disrupt the Ndufs4 gene, which encodes a 18 kDa subunit of
complex I that is not directly involved in electron transport but
which plays a role in assembly or stability of the entire complex
[19]. Ndufs4-null mice have been established as a model for Leigh
syndrome; a devastating early onset neurological disorder often
associated with mutations to respiratory complexes [19,20]. These
mice exhibit increasing ataxia and failure to thrive early in life, and
typically die by post-natal day 55 [19,20]. In contrast, a recently
developed heart specific Ndufs4-null mouse strain has no reported
pathological phenotype up to 1 year of age despite significant
inhibition of complex I activity [21]. Therefore, we employed this
heart specific Ndufs4-null mouse to explore how persistent
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inhibition of mitochondrial complex I activity affected cardiac
function specifically.
Here we demonstrate that selective disruption of the Ndufs4
gene in the heart leads to a ,50% decrease in complex I activity,
that in turn drives severe hypertrophic cardiomyopathy, as
determined by magnetic resonance imaging (MRI). However,
Ndufs4 gene ablation had no effect on mitochondrial hydrogen
peroxide levels, oxidative damage, apoptosis, or tissue fibrosis in
the heart. This work suggests that disruption to complex I alone is
sufficient to drive myocardial dysfunction. Furthermore, this
complex I driven cardiomyopathy occurs through disruption of




All animal experiments were carried out in accordance with the
UK Animals (Scientific Procedures) Act 1986 and the University
of Cambridge Animal Welfare Policy, and were approved by the
UK Home Office under project license 80/2374.
Mouse breeding and maintenance
The Ndufs4-null mouse model was a kind gift from the lab of
Prof Nils Göran-Larsson, Max Planck Institute for Ageing,
Cologne, Germany [21].
Previously, these mice were generated by breeding Ndufs4Loxp/+
mice with mice carrying the heart specific cre recombinase,
CKM-NLS-cre and established on a C57Bl/6 background
[22,23]. Then double heterozygous offspring were crossed to
obtain homozygous Ndufs4LoxP/LoxP mice [21]. In order to
generate littermate knockout (CKM-NLS-cre; Ndufs4LoxP/LoxP)
and control mice, the male CKM-NLS-cre knockouts (CKM-
NLS-cre; Ndufs4LoxP/LoxP) were crossed to control females
(Ndufs4LoxP/LoxP). Mice with genotype Ndufs4+/LoxP or Nduf-
s4LoxP/LoxP were used as controls [21]. A mix of CKM-NLS-cre;
Ndufs4LoxP/LoxP males and females between the ages of 8–24
weeks were used for all experiments. As described previously,
within this age range there was no discernable difference in health,
appearance or behaviour between heart-specific Ndufs4-null mice
and controls.
Magnetic resonance imaging of heart function
Animals (8–24 weeks of age) were anaesthetized with gaseous
isoflurane both for induction (3% in 1 l/min O2) and maintenance
(1.25–2% in 1 l/min O2). A pressure sensor for respiration rate
was used to monitor anaesthesia depth, breathing rate was
maintained in the range 30–60 breaths per minute. Prospective
gating of the MRI sequences was achieved with ECG monitoring.
Body temperature was monitored using a rectal thermometer and
kept constant at 37uC using a water-heated blanket.
Cine MRI was performed at 4.7 T with a Bruker BioSpec 47/
40 system (Bruker Inc., Ettlingen, Germany)[24]. A quadrature
birdcage coil of 12 cm was used for signal excitation and a four-
channel cardiac receiver coil for signal reception. Animals were
positioned prone. After initial localization images, long axis views
were acquired. Using these scans as a reference, short axis slices
were arranged perpendicularly to both the long-axis views to cover
the LV (FISP, TR/TE 6 ms/2.1 ms, 13–20 frames, 3.5 cm FOV,
2566256 matrix, 1 mm slice thickness, bandwidth 78 kHz, flip
angle 20u, NEX 1). Full LV coverage was achieved with no slice
gap with 8–10 slices.
After the acquisition of the standard protocol, MRI was
performed using a multi-slice inversion recovery sequence as
described previously.
For image analysis the papillary muscles and trabeculations
were excluded from the delineation of the LV at each phase of the
cardiac cycle. The regions from each slice were combined using
Simpson’s rule to provide LV mass, end diastolic volume, end
systolic volume, stroke volume and ejection fraction using Segment
v1.9 [25].
Measurement of complex I activity
Mitochondrial complex I activity was assessed as described
previously [7]. Briefly, mitochondria were isolated from entire
hearts by differential centrifugation [26] and 100 mg mitochon-
drial protein was resuspended in a 10 mM HEPES, 120 mM KCl
assay buffer containing 100 mM NADH, 10 mM decylubiquinone,
300 nM antimycin, 2 mM potassium cyanide, and 30 mg/ml
alamethicin and incubated for 5 min at 32uC while the rate of
absorbance change was determined at 340 nm. The background
rate following addition of 4 mg/ml rotenone was subtracted from
the NADH:decylubiquinone rate. In parallel, the citrate synthase
activity of each sample was determined as described previously [7].
The complex I rate was normalized to the citrate synthase rate,
and then expressed as a % of the appropriate control.
Measurement of mitochondrial hydrogen peroxide level
in vivo
Mitochondrial hydrogen peroxide was measured in vivo using
the MitoB mass spectrometric probe as described previously
[7,27]. Briefly, 75 nmol MitoB (,3 mmol/kg for 25–30 g mice) in
50 ml saline was administered by tail vein injection to the mouse.
2 hours following injection the entire heart was frozen in liquid
nitrogen and then stored at 280uC. For analysis the tissues were
homogenized and spiked with deuterated internal standards,
extracted, and the content of MitoB and MitoP determined by
liquid chromatography and tandem mass spectrometry as
described previously [27].
Measurement of protein carbonylation
Protein carbonylation levels in the heart were determined by
rapid homogenization of entire hearts and protein quantification
of heart homogenate, followed by quantification of protein
carbonyls using the BioCell Protein Carbonyl Assay Kit according
to the manufacturers instructions.
Measurement of apoptosis activation
The expression of caspase 3 and cleaved caspase 3 (Cell
Signaling Technologies, 1:1000 dilution) was analyzed by standard
Western blotting techniques. The band intensity of three
independent experiments was measured using SigmaGel software
and normalized to Actin (Cell Signaling Technologies, 1:1000
dilution).
Measurement of MnSOD levels
The expression of manganese superoxide dismutase (MnSOD)
(Cell Signaling Technologies, 1:1000 dilution) was analyzed by
standard Western blotting techniques. The band intensity of three
independent experiments was measured using SigmaGel software
and normalized to Actin (Cell Signaling Technologies, 1:1000
dilution).
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Histological staining for fibrosis
Hearts were excised, stored overnight in 10% formalin and
embedded in paraffin before 9 mircons thick section were taken
throughout the heart. Masson’s Trichrome staining was performed
according to the manufacturers specifications (HT15, St. Louis,
MO, USA). Briefly, slides were deparaffinized in deionized water
and fixed in Bouin’s solution. After washing and incubation in
Weigert’s Irono Heamatoxylin solution, the slides were incubated
in Biebrich Scarlet Acid Fuchsin and Anilin Blue solution for
staining. Finally the slides were dehydrated in ethanol and
mounted. The nuclei were stained black, the collagen fibers blue
and muscles red
Statistics
Data are presented as mean 6 standard error from the mean.
Statistical analysis was performed using one-way ANOVA. The
differences were considered significant at P,0.05.
Figure 1. Complex I activity in control and Ndufs4-null mouse hearts. Mitochondria isolated from mouse hearts were assessed for rotenone-
sensitive NADH:decylubiquinone activity. To control for mitochondrial content from heart isolations, complex I activity was expressed as a function of
citrate synthase activity from the same hearts. n = 6, ** p,0.01.
doi:10.1371/journal.pone.0094157.g001
Figure 2. Cardiac function assessed by MRI. a, Left ventricular ejection fraction (LVEF) of control and Ndufs4-null mouse hearts assessed in vivo
by MRI. b, LVEF comparison by sex and c, age. d, left ventricular stroke volume (LVSV) of control and Ndufs4-null mouse hearts assessed in vivo by
MRI. n = 2–8, ** p,0.001.
doi:10.1371/journal.pone.0094157.g002
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Results and Discussion
To study how partial disruption of complex I activity impacted
on heart function, we used the recently developed heart-specific
Ndufs4-null mouse model [21]. As expected, Ndufs4-null mice
exhibited ,50% lower myocardial complex I activity compared to
controls (Fig. 1). This activity of complex I in the Ndufs4-null mice
was higher than previously reported, which was reported as less
than 5% residual activity [21]. This discrepancy is perhaps
explained by our use of decylubiquinone as an electron acceptor in
contrast to previous assessments which used coenzyme Q1 [21],
which is a less effective complex I substrate than decylubiquinone
[28]. Supporting this interpretation, the previous study also
observed a combined complex I/complex III activity in the
Ndufs4-null mouse that was ,21% of control levels [21], consistent
with their assessment of complex I activity using coenzyme Q1
underestimating complex I activity. Therefore, we are confident
that the heart selective ablation of the Ndufs4 gene leads to a
decrease in complex I activity of about 50%, similar to that found
in a number of pathologies [5,8,9,14–16], making this model an
effective test for the consequences of complex I disruption on
cardiac dysfunction.
We next assessed the effects of partial complex I disruption
through Ndufs4 ablation on heart function using MRI (Videos S1
and S2). MRI is the current ‘‘gold standard’’ method for clinical
assessment of myocardial function and left ventricular mass, which
have been established as sensitive predictors of adverse outcomes
in hypertrophic cardiomyopathies [29]. Left ventricular ejection
Figure 3. Cardiac morphology assessed by MRI. a, Left ventricular mass (LVM) of control and Ndufs4-null mouse hearts. b, representative long-
axis views of the end systole and c, quantification of left ventricular end systolic volume (LVESV) of control and Ndufs4-null mouse hearts. d,
representative long-axis views of the end distole and e, left ventricular end diastolic volume (LVEDV) of control and Ndufs4-null mouse hearts. All
parameters assessed in vivo by MRI. f, Representative heart slices after Masson trichrome staining of control and Ndufs4-null hearts. n = 4–8, * p,0.05,
** p,0.001.
doi:10.1371/journal.pone.0094157.g003
Complex I Deficiency Results in Cardiomyopathy
PLOS ONE | www.plosone.org 4 April 2014 | Volume 9 | Issue 4 | e94157
fraction (LVEF) was significantly lower in Ndufs4-null mice
(26.8%64.0% versus 67.1%62.6% in control mice, p,0.001;
Fig. 2a). Decreased LVEF was substantial in both male and female
mice, with male mice potentially exhibiting a more severe effect
(Fig. 2b), although the difference between sexes was not statistically
significant. Additionally, the observed difference in LVEF between
wild-type and Ndufs4-null mice was consistent throughout early life
(Fig. 2c) A concomitant decrease in left ventricular stroke volume
(LVSV) was also observed in Ndufs4-null mice; (17.2 ml62.8 ml
versus 37.50 ml60.46 ml in control mice, p,0.001; Fig. 2d).
In addition, left ventricular mass (LVM) was significantly higher in
Ndufs4-null mice (119.0 ml66.96 ml versus 95.75 ml63.17 ml in
controls, p = 0.005; Fig. 3a). LVM increases were paralleled by a
nearly threefold increase in left ventricular end-systolic volume
(LVESV, 47.17 ml64.72 ml versus 18.75 ml62.38 ml in controls, p,
0.001; Fig. 3b and c). Furthermore, there was no significant
difference observed in left ventricular end-diastolic volume (LVEDV)
between groups (Fig. 3d and e). We next determined whether the
severe defects in cardiac function and increase in LVM initiated by
Ndufs4 ablation were accompanied by activation of tissue fibrosis, but
found no detectable evidence for fibrotic remodeling (Fig. 3f).
Complex I is a major source of mitochondrial ROS, and
cardiomyopathies are frequently associated with increased ROS
levels [30–32]. A decrease in complex I activity could lead to an
increase in mitochondrial NADH levels, which would in turn lead
to an elevation of superoxide production by complex I and other
sources [12]. Therefore, we next assessed whether Ndufs4-null
mediated hypertrophic cardiomyopathy correlated with changes in
mitochondrial ROS levels. To do so we used the recently
developed MitoB probe for in vivo quantification of mitochondrial
hydrogen peroxide production [27]. Interestingly, Ndufs4-null
mouse hearts exhibited mitochondrial hydrogen peroxide levels
indistinguishable from controls (Fig. 4a). Importantly, assessment
of mitochondrial hydrogen peroxide in vivo is a reliable surrogate
for levels of the proximal mitochondrial ROS, superoxide, since
mitochondria have micromolar concentrations of MnSOD which
reacts with superoxide extremely rapidly (k<2.36109 M21?s21) to
form mitochondrial hydrogen peroxide [12]. In parallel, we also
measured the levels of the MnSOD in mild-type and Ndufs4-null
mouse hearts to compare the endogenous superoxide dismutation
capacity, finding levels to be comparable (Fig. 4b,c). In addition,
measurement of protein carbonyls as an indication of oxidative
damage showed that Ndufs4-null mouse hearts were similar to
control hearts (Fig. 4d). Finally, we determined whether Ndufs4
ablation initiated apoptosis by measuring cleavage and activation
of caspase 3. While wild-type and Ndufs4-null mouse hearts had
comparable levels of full length caspase 3, in both groups cleaved
caspase 3 was undetectable (Fig. 4e,f). Together these findings
indicated that the observed development of severe hypertrophic
cardiomyopathy due to complex I disruption occurred indepen-
dently of changes in mitochondrial hydrogen peroxide levels,
oxidative damage, or apoptosis.
Here we have demonstrated that moderate and chronic
disruption of mitochondrial complex I activity through heart-
Figure 4. Assessment of mitochondrial ROS and apoptosis. a, in vivo mitochondrial hydrogen peroxide levels quantified using the ratiometric
mass spectrometry probe MitoB. Hearts isolated from control and Ndufs4-null mice injected with MitoB are assessed by MS for MitoB and MitoP levels
and the level of mitochondrial hydrogen peroxide are expressed as the ratio of MitoP to MitoB. b, Immunoblot determination and c, densitometry of
MnSOD expression in control and Ndufs4-null hearts. d, Quantification of in vivo protein carbonylation in control and Ndufs4-null hearts. e,
Immunoblot determination and f, densitometry of Caspase-3 expression and cleavage in control and Ndufs4-null hearts. n = 3–5.
doi:10.1371/journal.pone.0094157.g004
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specific ablation of the Ndufs4 gene is sufficient to drive severe
hypertrophic cardiomyopathy as determined by MRI. These gross
pathological changes occur independently of alterations in mito-
chondrial hydrogen peroxide levels, oxidative damage, or apoptosis.
Together these results suggest a primary role for complex I activity
in driving the pathophysiological processes that lead to cardiomy-
opathy. Furthermore, complex I driven cardiomypathy occurs
independently of aberrant ROS production and is thus primarily
due to defective complex I activity that impacts on cardiac function
by disrupting bioenergetic parameters in the heart.
Supporting Information
Video S1 Long-axis MRI view of heart function of
control mouse hearts.
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